



DIGITAL BIOMARKERS & DIGITAL MEASUREMENTS

FOSTERING THE NEW AGE OF HEALTH

Tuesday 26th & Wednesday 27th October 2021

Virtual

Conference Day 1. Tuesday 26th October

8:00am Registration, Breakfast and Networking

9:00am Chair's Opening Remarks

Dan Karlin, Chief Medical Officer, [Mindmed](#)

9:15am Keynote Presentation: An Industry Overview from the DiMe Society

- How is DiMe driving scientific progress and broad acceptance of Digital medicine to enhance public health.
- Take a look at how we as an industry can utilise our expertise and responsibilities concerning the use of digital tools.
- Understand why effective, unambiguous communication is essential for efficient translation of promising scientific discoveries into approved medical products.

Jennifer Goldsack, Chief Executive Officer, [DiMe](#)

9:40 Panel Discussion and Open Q&A: Digital Biomarkers & Digital Measurements: The Story So Far

- What have we learnt over the past year?
- Where are we now as a community?
- Where does pharma stand on adoption of Digital Biomarkers and Measurements?
- What challenges do we need to overcome in the field, in order to deliver the full potential of Digital Biomarkers & Digital Measurements?

Rob Goldel, [Neuroscientist and Technologist](#)

Christine Manta, Head of Applied Sciences, [HumanFirst FKA Elektra labs](#)

Rebecca Kirch, [National Patient Advocate Foundation](#)

Krishna Jhaveri, Senior Clinical Lead, [Philips](#)

Robert J. Mather, Executive Director, Early Clinical Development, [Pfizer](#)

Moderator: Jennifer Goldsack, Chief Executive Officer, [DiMe](#)

10.25am

Morning Refreshments & Networking

11:05am Presentation: Case Study of Clinical Trials from Genentech. What has Worked and What Hasn't?

- An insight into Genentech's digital case studies
- What are the learnings from previous studies and how, as an industry, can we improve clinical trials utilizing digital?
- How have Genentech overcome challenges faced during clinical trials?

Victoria Whitehill, Innovation Strategy Lead, [Genentech](#)

11:25am Co-Presentation: Gait Up & MedRhythms Successful Industry Partnership

- MedRhythms incorporation of Gait Up's proprietary sensors and gait measurement algorithms into its digital therapeutics platform for people with neurologic injuries and diseases.
- Learn about how this collaboration worked so well to make a successful industry partnership.
- The missions driving MedRhythms and Gait Up are aligned in that they both aim to improve lives by improving movement.

Patrick Pestalozzi, Managing Director, [Gait Up](#)

Owen McCarthy, Co-founder & President, [MedRhythms](#)

11:45am Panel Discussion and Open Q&A: How to Streamline Clinical Trials in Order to Benefit Patients, Clinicians, Researchers and Pharma

Previously, on site clinical trials have been very brief, limited, episodic and relied partly on subjective data. In contrast, how can decentralized clinical trials benefit pharma, clinicians and their patients?

- A comparison between site-based and decentralized trials
- How can we maintain clinical efficacy and safety in decentralized trials?
- What are the scientific, operational and financial challenges that might need to be addressed before wearables, portables, digestables ect can consistently create impact for Pharma?
- How can virtualization tackle the challenge of inclusion in clinical trials?
- How do we envision hybrid clinical trials working?

Ben Schlatka, Vice President, Digital Biomarker Solutions, [Medidata](#)

Tim Callahan, Vice President, Scientific Affairs, [BioTel Research, A Philips Company](#)

Melinda Decker, Chief Commercial Officer & Digital Health Advisor, [Mymee](#)
Aman Thukral, Director & Head, Clinical Systems & Digital Operations, [Abbvie](#)

12:30pm

Lunch & Networking

The Digital Biomarkers & Digital Measurements Summit includes an extended break in the middle of the day to give you ample time for lunch and another chance for 1-2-1 meetings or open networking.

1:45pm Presentation: High-frequency active assessments: Remote burst testing techniques and enhancing contextual insight to passive physiological measures

- Understand how Cambridge Cognition are using scientifically validated digital health solutions
- How do we optimize the assessment of cognition for better brain health research?
- Cambridge Cognitions technology enables efficient, non-invasive means of assaying brain function and participant outcomes, improving clinical trials and accelerating decision-making.

Nathan Cashdollar, PhD, Director of Digital Neuroscience, [Cambridge Cognition](#)

2:10pm Panel Discussion and Open Q&A: Assessing Digital Biomarkers as Clinical Endpoints: Standardization and Validation

- What are Digital Endpoints?
- What regulatory progress has been made so far for Digital Biomarkers?
- What approaches are there to evaluating Digital Biomarkers?
- Are we missing important clinical validation data?
- How do we overcome these obstacles in validation of novel digital endpoints?

Carrie Northcott, Director, [Pfizer](#)

Ariel Dowling, Director of Digital Strategy, [Takeda](#)

Kathryn Papp, Clinical Neuropsychologist, Assistant Professor, [Harvard Medical School](#)

Andy Coravos, Co-founder & Chief Executive Officer, [HumanFirst FKA Elektra Labs](#)

Ida Sim, MD, PhD, Professor of Medicine, [University of California, San Francisco](#); Co-Founder, [Open mHealth](#); Co-Founder, [Vivli](#)

Nathan Cashdollar, PhD, Director of Digital Neuroscience, [Cambridge Cognition](#)

2:55pm

Afternoon Refreshments & Networking

3:45pm Lightning Talk 1. With Q&A - Cyber Security and Integrity Considerations with Complex Supply Chains.

Beau Woods, Deputy Director, Cyber Safety Innovation Fellow, [Atlantic Council](#)

4:05pm Lightning Talk 3. With Q&A- Demo of Kaia Healths Digital Biomarker Experience

Chris Richter, Senior Data Scientist, [Kaia Health](#)

4.30pm Panel Discussion: How Do We Increase Adoption of Digital Biomarkers by Enhancing Usability of Digital Technology for The Patients?

- How can we make Digital technology user-friendly whilst still maintaining sensitivity?
- How relevant are these Digital Biomarkers & Measurements to the patients personal outcomes?
- What barriers are there to adoption of Digital Biomarkers and Measurements?
- Can we use certain biomarkers to track the progression of many different diseases?
- Regarding the data gathered, can we use this in multiple different ways?

Chris Richter, Senior Data Scientist, [Kaia Health](#)

Jessica Robin, Director, Clinical Research, [Winterlight Labs](#)

Roozbeh Ghaffari, Chief Executive Officer & Co-Founder, [Epicore Biosystems](#)

Benjamin Vandendriessche, Chief Medical Officer, [Byteflies](#)

Jennifer Horonjeff, Founder & Chief Executive Officer, [Savvy Cooperative](#)

5:15pm Chairs Closing Remarks of Day 1.

Conference day 2. Wednesday 27th October

8:00am Sign in, Breakfast & Networking

9:00am Chairs Opening Remarks

Carrie Northcott, Director, [Pfizer](#)

9:10am Presentation: The Asthma Digital Study

Siavash Sarlati, Medical Director, Digital Technologies, [Anthem](#)

9:35am Panel Discussion and Open Q&A: Aligning Our Incentives for Long Term Data Collection. All the Way From Early R&D Through to The Patient.

- How can we drive long term engagement and retention?
- Does the patient feel like more data collection will enable their physician to take better care of them?
- How long is 'long term'?
- Why do we need long term data collection and what are the benefits of more?
- What are the benefits of long term data collection to each stakeholder?

Vaibhav Narayan, Vice President Data Science, [Janssen](#)

Jessilyn Dunn, Assistant Professor of Biomedical Engineering, [Duke University](#)

Yvonne Chan, Founder, [Agile Science Consulting LLC](#)

Christine Guo, Chief Scientific Officer, [ActiGraph](#)

10:15am Closing Panel Discussion Part A: Holistic Measurements- Is The Patient Just the Sum of Their Diseases?

- What does it mean to measure a whole person?
- How sensitive can we make and do we need to make these Digital measurements?
- What other information do we need in order to come to conclusions about patients' health?
- Will there be different sensitivity levels when looking at common and rare diseases?
- How might holistic measurements generate stronger and more reliable conclusions about patients' health?

Peter Bergethon, Vice President Digital & Quantitative Data, [Biogen](#)

Dan Karlin, Chief Medical Officer, [Mindmed](#)

Thomas Switzer, Digital Health Scientist, Genentech Research and Early Development (gRED), [Genentech](#)

Clemens Becker, MD, Lead of Mobilised-D clinical Validation Study, Head of Department Geriatric Medicine, [University of Heidelberg](#)

Mette Dyhrberg, Founder & Chief Executive Officer, [Mymee](#)

10:55am

Morning refreshments and Networking

11:25am Closing Panel Discussion Part B: Where Does The Future Lie for Digital Biomarkers and Digital Measurements?

- What are the limitations of Digital Biomarkers? Many have been discovered for some disease states and not so many for others.
- Could there be cross industry collaboration?
- How can we expand our learning so that it carries on through to successful Digital Therapeutics?
- How can we use Digital Biomarkers and Measurements proactively, to ensure early intervention before disease onset?
- What tips would the panelists give the audience to steer Digital Biomarkers and Digital Measurements into everyday healthcare?

Peter Bergethon, Vice President Digital & Quantitative Data, [Biogen](#)

Dan Karlin, Chief Medical Officer, [Mindmed](#)

Joss Langford, Founder & Chief Technology Officer, [ActivInsights](#)

Shoibal Datta, Head of R&D Digital Strategy Group, [Takeda](#)

Kate Lyden, Chief Science Officer, [VivoSense](#)

Liam Kaufman, Co-founder & Chief Executive Officer, [Winterlight Labs](#)

12:05pm Chairs closing remarks

Carrie Northcott, Director, [Pfizer](#)

12:20pm

End of Digital Biomarkers & Digital Measurements Summit 2021